ArticleCureus2025
A Case Report of Progressive Multifocal Leukoencephalopathy (PML) in an Immunocompetent Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive multifocal leukoencephalopathy (PML) is a rare but fatal demyelinating disorder resulting from reactivation of latent John Cunningham virus (JCV), which induces demyelinating lytic infection of oligodendrocytes. We report a case of PML in an individual without identifiable immunodeficiency who presented with insidious and progressive deficits in speech and motor function. Diagnostic workup revealed JC viral DNA in cerebrospinal fluid, and magnetic resonance imaging (MRI) demonstrated multiple asymmetric lesions within the subcortical and deep white matter. Despite administration of the immune checkpoint inhibitor pembrolizumab, the patient's neurological status continued to decline, culminating in death. This case underscores the necessity of considering PML in the differential diagnosis of patients lacking classic risk factors when clinical presentation and neuroimaging findings are indicative of demyelinating pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.